240 related articles for article (PubMed ID: 19276681)
1. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells.
Zhang F; Beharry ZM; Harris TE; Lilly MB; Smith CD; Mahajan S; Kraft AS
Cancer Biol Ther; 2009 May; 8(9):846-53. PubMed ID: 19276681
[TBL] [Abstract][Full Text] [Related]
2. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40.
Vander Haar E; Lee SI; Bandhakavi S; Griffin TJ; Kim DH
Nat Cell Biol; 2007 Mar; 9(3):316-23. PubMed ID: 17277771
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of insulin-stimulated 4E-BP protein binding to mammalian target of rapamycin (mTOR) complex 1 and its contribution to mTOR complex 1 signaling.
Rapley J; Oshiro N; Ortiz-Vega S; Avruch J
J Biol Chem; 2011 Nov; 286(44):38043-38053. PubMed ID: 21914810
[TBL] [Abstract][Full Text] [Related]
4. Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation.
Wang L; Harris TE; Lawrence JC
J Biol Chem; 2008 Jun; 283(23):15619-27. PubMed ID: 18372248
[TBL] [Abstract][Full Text] [Related]
5. PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection.
Chong ZZ; Shang YC; Wang S; Maiese K
PLoS One; 2012; 7(9):e45456. PubMed ID: 23029019
[TBL] [Abstract][Full Text] [Related]
6. Alcohol and PRAS40 knockdown decrease mTOR activity and protein synthesis via AMPK signaling and changes in mTORC1 interaction.
Hong-Brown LQ; Brown CR; Kazi AA; Huber DS; Pruznak AM; Lang CH
J Cell Biochem; 2010 Apr; 109(6):1172-84. PubMed ID: 20127721
[TBL] [Abstract][Full Text] [Related]
7. PRAS40 plays a pivotal role in protecting against stroke by linking the Akt and mTOR pathways.
Xiong X; Xie R; Zhang H; Gu L; Xie W; Cheng M; Jian Z; Kovacina K; Zhao H
Neurobiol Dis; 2014 Jun; 66():43-52. PubMed ID: 24583056
[TBL] [Abstract][Full Text] [Related]
8. Pim1 inhibition as a novel therapeutic strategy for Alzheimer's disease.
Velazquez R; Shaw DM; Caccamo A; Oddo S
Mol Neurodegener; 2016 Jul; 11(1):52. PubMed ID: 27412291
[TBL] [Abstract][Full Text] [Related]
9. Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis.
Huang B; Porter G
Acta Pharmacol Sin; 2005 Oct; 26(10):1253-8. PubMed ID: 16174443
[TBL] [Abstract][Full Text] [Related]
10. Role of PRAS40 in Akt and mTOR signaling in health and disease.
Wiza C; Nascimento EB; Ouwens DM
Am J Physiol Endocrinol Metab; 2012 Jun; 302(12):E1453-60. PubMed ID: 22354785
[TBL] [Abstract][Full Text] [Related]
11. AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.
Mi W; Ye Q; Liu S; She QB
Oncotarget; 2015 Jun; 6(16):13962-77. PubMed ID: 25961827
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases inhibition of mTORC1 and promotes tumor growth.
Padi SKR; Singh N; Bearss JJ; Olive V; Song JH; Cardó-Vila M; Kraft AS; Okumura K
Proc Natl Acad Sci U S A; 2019 Oct; 116(41):20505-20510. PubMed ID: 31548394
[TBL] [Abstract][Full Text] [Related]
13. Role of PIM Kinase Inhibitor in the Treatment of Alzheimer's Disease.
Meur S; Mukherjee S; Roy S; Karati D
Mol Neurobiol; 2024 May; ():. PubMed ID: 38816674
[TBL] [Abstract][Full Text] [Related]
14. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
Zang C; Eucker J; Liu H; Müller A; Possinger K; Scholz CW
Cancer Lett; 2013 Oct; 339(2):288-97. PubMed ID: 23200668
[TBL] [Abstract][Full Text] [Related]
15. Targeting PRAS40: a novel therapeutic strategy for human diseases.
Zhou Q; Tang S; Zhang X; Chen L
J Drug Target; 2021 Aug; 29(7):703-715. PubMed ID: 33504218
[TBL] [Abstract][Full Text] [Related]
16. PRAS40 alleviates neurotoxic prion peptide-induced apoptosis via mTOR-AKT signaling.
Yang W; Yang LF; Song ZQ; Shah SZA; Cui YY; Li CS; Zhao HF; Gao HL; Zhou XM; Zhao DM
CNS Neurosci Ther; 2017 May; 23(5):416-427. PubMed ID: 28294542
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of a proline-rich Akt substrate (PRAS40) in human copper/zinc-superoxide dismutase transgenic rats protects motor neurons from death after spinal cord injury.
Yu F; Narasimhan P; Saito A; Liu J; Chan PH
J Cereb Blood Flow Metab; 2008 Jan; 28(1):44-52. PubMed ID: 17457363
[TBL] [Abstract][Full Text] [Related]
18. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
19. Signal transduction pathways in FSH regulation of rat Sertoli cell proliferation.
Riera MF; Regueira M; Galardo MN; Pellizzari EH; Meroni SB; Cigorraga SB
Am J Physiol Endocrinol Metab; 2012 Apr; 302(8):E914-23. PubMed ID: 22275758
[TBL] [Abstract][Full Text] [Related]
20. Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40.
Basu A; Banerjee P; Contreras AG; Flynn E; Pal S
PLoS One; 2011; 6(8):e23919. PubMed ID: 21886838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
